Trials / Completed
CompletedNCT01044342
A Healthy Volunteer Study to Evaluate Reversibility of Induced Impairment of Cognition
A Single-centre, Randomised, Double-blind, Placebo-controlled, Four-period Cross-over Study to Evaluate the Scopolamine Cognition Model in Healthy Male Subjects Using AZD1446 and Donepezil Versus Placebo
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine if cognitive impairment induced by scopolamine is reversed using donepezil and/or AZD1446 as compared to placebo, as assessed by electroencephalogram (EEG) measures.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD1446 | capsule; single oral dose |
| DRUG | AZD1446 | capsule, single oral dose |
| DRUG | donepezil | capsule, single oral dose |
| DRUG | Placebo | capsule, single oral dose |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2010-04-01
- Completion
- 2010-04-01
- First posted
- 2010-01-07
- Last updated
- 2010-05-10
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01044342. Inclusion in this directory is not an endorsement.